Ranbaxy Laboratories’ OTC business division-Ranbaxy Global Consumer Healthcare has launched ‘Volini Duo’, India’s first approved two in one pain killer, a unique bi-layered Acetminophen tablet, specially formulated to give dual pain relief. The product has been introduced pan India.
‘Volini Duo’ has been developed by scientist at company’s state of art R&D centre in Gurgaon, using Metrix technology, which enables the regulated release of the medicine in the gastrointestinal tract. It is specifically effective for back and joint pains, which are primarily chronic in nature.
Volini Duo tablet marks the entry of Ranbaxy in the OTC oral pain reliever category. The OTC oral analgesics market in India is estimated to be Rs 700 crore and is growing annually at the rate of 10.5%.
Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1279.70 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2245.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: